Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MediWound Ltd. is a fully-integrated biopharmaceutical company focused on developing, manufacturing, and commercializing innovative, cost-effective biotherapeutic solutions for tissue repair and regeneration. Their core mission is to address unmet medical needs in the fields of severe burn care and chronic wound management. Key products include NexoBrid®, an orphan biologic drug for eschar removal in adults with deep partial and full-thickness thermal burns, and EscharEx®, an investigational biological drug candidate for the debridement of chronic and other hard-to-heal wounds. MediWound leverages its enzymatic technology platform and robust R&D pipeline to provide novel treatments that aim to improve clinical outcomes and enhance the quality of life for patients worldwide.
The Yavne headquarters serves as the company's principal executive, administrative, research and development (R&D), and manufacturing center for its portfolio of biopharmaceutical products.
The facility is equipped with advanced laboratories for cutting-edge R&D and cGMP-compliant manufacturing suites designed to meet stringent international pharmaceutical standards.
MediWound cultivates a work culture centered on innovation, collaboration, and scientific rigor. Employees are driven by a shared commitment to advancing medical science and making a tangible difference in patients' lives.
This central hub is pivotal to MediWound's entire value chain, from initial drug discovery and clinical development to global manufacturing, commercial strategy, and corporate governance.
MediWound supports its global operations from its headquarters in Israel and its European office in Germany. The company's products are commercialized in multiple international markets through a combination of direct sales efforts and strategic partnerships with leading healthcare companies. For instance, NexoBrid® is commercialized in North America by Vericel Corporation. MediWound actively conducts clinical trials in various countries to expand product indications and secure regulatory approvals, thereby broadening its international market reach and patient access.
42 Hayarkon Street
Yavne
Central District
Israel
Address: Augusta Anlage 33, 68165 Mannheim, Germany
To support the commercialization and distribution of MediWound's products across Europe, engage with European healthcare professionals and regulatory bodies, and manage regional partnerships.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MediWound' leadership includes:
MediWound has been backed by several prominent investors over the years, including:
MediWound has seen key leadership transitions in the past year, notably with the appointment of a new CEO and a new CFO to steer the company's strategic growth and financial operations.
Discover the tools MediWound uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While MediWound Ltd. does not publicly disclose its official email format, a common pattern used by companies of similar size and structure in the biopharmaceutical industry is [first_initial][last]@mediwound.com or [first].[last]@mediwound.com. This is an educated estimation.
[first_initial][last]@mediwound.com
Format
ogonen@mediwound.com
Example
75%
Success rate
MediWound Ltd. Press Release • April 29, 2024
MediWound reported the enrollment of the first patient in its pivotal U.S. Phase III study (SafeDebride Study) evaluating EscharEx® for the debridement of venous leg ulcers. This marks a significant step in advancing EscharEx® towards potential U.S. market approval....more
MediWound Ltd. Press Release • March 25, 2024
MediWound announced its financial results for the full year ended December 31, 2023, highlighting key achievements, including progress with NexoBrid® commercialization and EscharEx® development, alongside its financial performance and outlook for 2024....more
MediWound Ltd. Press Release • February 20, 2024
A landmark achievement for MediWound, the U.S. Food and Drug Administration (FDA) cleared the Biologics License Application (BLA) for NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. This clearance paves the way for its U.S. launch by Vericel....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MediWound, are just a search away.